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ABSTRACT
Objective To develop and validate two new fracture risk
algorithms (QFractureScores) for estimating the individual
risk of osteoporotic fracture or hip fracture over 10 years.
Design Prospective open cohort study with routinely
collected data from 357 general practices to develop the
scores and from 178 practices to validate the scores.
Setting General practices in England and Wales.
Participants 1183663 women and 1174232 men aged
30-85inthederivationcohort,whocontributed7898208
and 8049306 person years of observation, respectively.
There were 24350 incident diagnoses of osteoporotic
fracture in women and 7934 in men, and 9302 incident
diagnoses of hip fracture in women and 5424 in men.
Main outcome measures First (incident) diagnosis of
osteoporotic fracture (vertebral, distal radius, or hip) and
incident hip fracturerecordedin generalpracticerecords.
Results Use of hormone replacement therapy (HRT), age,
bodymassindex(BMI),smokingstatus,recordedalcohol
use, parental history of osteoporosis, rheumatoid
arthritis, cardiovascular disease, type 2 diabetes,
asthma,tricyclicantidepressants,corticosteroids,history
of falls, menopausal symptoms, chronic liver disease,
gastrointestinal malabsorption, and other endocrine
disorders were significantly and independently
associated with risk of osteoporotic fracture in women.
Some variables were significantly associated with risk of
osteoporotic fracture but not with risk of hip fracture. The
predictors for men for osteoporotic and hip fracture were
age, BMI, smoking status, recorded alcohol use,
rheumatoid arthritis, cardiovascular disease, type 2
diabetes, asthma, tricyclic antidepressants,
corticosteroids, history of falls, and liver disease. The hip
fracture algorithm had the best performance among men
and women. It explained 63.94% of the variation in
womenand63.19%ofthevariationinmen.TheDstatistic
values for discrimination were highest for hip fracture in
women (2.73) and men (2.68) and were over twice the
magnitude of the corresponding values for osteoporotic
fracture.TheROCstatisticsforhipfracturewerealsohigh:
0.89 in women and 0.86 for men versus 0.79 and 0.69,
respectively, for the osteoporotic fracture outcome. The
algorithms were well calibrated with predicted risks
closely matching observed risks. The QFractureScore for
hipfracturealsohadgoodperformancefordiscrimination
and calibration compared with the FRAX (fracture risk
assessment) algorithm.
Conclusions These new algorithms can predict risk of
fracture in primary care populations in the UK without
laboratory measurements and are therefore suitable for
use in both clinical settings and for self assessment
(www.qfracture.org). QFractureScores could be used to
identify patients at high risk of fracture who might benefit
from interventions to reduce their risk.
INTRODUCTION
Osteoporotic fractures are a major and increasing
cause of morbidity in the population and a consider-
able burden to health services. Hip fractures, in parti-
cular, result in considerable pain, loss of function, and
admissiontohospital,makingpreventionahighprior-
ity for patients and physicians and for public health.
Various therapeutic and lifestyle interventions might
reduce the risk of osteoporosis and hence an indivi-
dual’s risk of fracture.
1 The challenge now is to
improve methods for accurate identification of indivi-
dualsathighriskwhomightbenefitfromatherapeutic
or preventive intervention. While there is no univer-
sallyacceptedpolicyforscreeningforpatientsatriskof
osteoporotic fracture, some guidelines,
2-5 but not all,
6
recommend a targeted approach to the prevention of
osteoporosis based on the 10 year absolute risk of
major osteoporotic fracture. Risk prediction utilities
are therefore required to accurately estimate indivi-
dual risk as well as enable a systematic targeted popu-
lation based screening approach.
Traditional approaches based on measurement of
bone mineral density alone are unsuitable for popula-
tion screening because of cost and low sensitivity.
7
Most fractures occur in women with normal bone
mineral density,
8 and the evidence suggests that risk
predictionalgorithmsthatdonotincludebonemineral
density are almost as good as those that do.
9 We need
less expensive and more practical methods of identify-
ing those at high risk; these should ideally be based on
models developed from contemporaneous data in
diverse populations representative of the clinical
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applied. Risk prediction utilities tend to perform best
in the settingsin which theyhave been derivedbothin
terms of discrimination (that is, ability to separate out
thosewhowillandwillnotdevelopafracture)andalso
calibration (how closely the overall predicted risk
matches the observed risk).
10
There are several established risk factors for osteo-
porotic fracture that could be used to derive a risk pre-
dictionalgorithmforusewithinprimarycare.Manyof
these risk factors are reliably recorded within primary
careclinicalcomputersystemsandhencesuchdatacan
be used to derive robust utilities that can then be
applied in primary care. The incidence of fracture
and the prevalence of associated risk factors will
change over time, and the methods to derive the risk
prediction algorithms need to be dynamic so that they
can be remodelled over time. UK datasets derived
from family practices have the advantage of having
large and broadly representative populations with his-
torical data tracking back well over a decade in most
practices, and they are continually updated.
Wedevelopedandvalidatedtwonewfractureclinical
risk scores (QFractureScores) derived from a large and
representative primary care population from a vali-
dated clinical research database (www.qresearch.org).
We analysed more than two million patients to address
someoftheresearchquestionsregardingriskfactorsfor
osteoporotic fracture in men and women highlighted
withintherecentNICEguidance,
6NationalOsteoporo-
sis Guideline,
5 and the World Health Organization.
11
We incorporated traditional variables already included
in the FRAX (fracture risk assessment) algorithm
7 and
added additional variables that affect risk of fracture,
such as history of falls, type 2 diabetes, cardiovascular
disease, asthma, use of hormone replacement therapy
(HRT), and use of tricyclic antidepressants.
512-14 We
alsoextendedtheagerangetoincludeyoungerpatients.
Lastly, we incorporated a more detailed categorisation
of alcohol and smoking status. Our new algorithm is
basedonvariablesthatare readilyavailableinpatients’
electronic primary healthcare records
15 or that the
patients themselves would probably know, without the
needforlaboratorytestsorclinicalmeasurements.This
approach is designed to enable the algorithms to be
readilyandcosteffectivelyimplementedinroutineclin-
ical practice or used by individual patients.
METHODS
Study design and data source
We conducted a prospective cohort study in a large
primary care population of patients from version 20
of the QResearch database. This is a large validated
primarycareelectronic databasecontaining the health
records of over 11 million patients registered from
574generalpracticesthatusetheEgtonMedicalInfor-
mationSystem(EMIS)computersystem.Practicesand
patients contained on the database are nationally
representative for England and Wales and similar to
those on other large national primary care databases
that use other clinical software systems.
16
Practice selection
We included all QResearch practices in England and
Wales once they had been using their current EMIS
system for at least a year to ensure completeness of
recording of morbidity and prescribing data. We ran-
domlyallocatedtwothirdsofpracticestothederivation
datasetandtheremainingthirdtothevalidationdataset;
the simple random sampling utility in Stata was used to
assign practices to the derivation or validation cohort.
Cohort selection
We identified an open cohort of patients aged 30-85 at
the study entry date, drawn from patients registered
with eligible practices during the 15 years between 1
January 1993 and 30 June 2008. We used an open
cohort design, rather than a closed cohort design, as
this allows patients to enter the population throughout
the wholestudyperiodratherthanrequireregistration
onafixeddate,reflectingtherealitiesofroutineclinical
practice. We excluded patients with a previous
recordedfracture(hip,distalradius,orvertebral),tem-
porary residents, patients with interrupted periods of
registration with the practice, and those who did not
have a valid Townsend deprivation score related to
the postcode (about 4% of the population).
For each patient,we determinedan entry date to the
cohort, which was the latest of the date of their 30th
birthday, date of registration with the practice, date
on which the practice computer system was installed
plus one year, and the beginning of the study period
(1 January 1993). We included patients in the analysis
onlyoncetheyhadaminimumofoneyear’scomplete
data in their medicalrecord.
17 Foreach patientwe also
determined an exit date, which was the earliest of date
of recorded fracture, date of death, date of deregistra-
tion with the practice, date of last upload of compu-
terised data, or the study end date (30 June 2008).
Primary outcomes
Our two primary outcomes were the first (incident)
diagnosis of an osteoporotic fracture (hip, vertebral, or
distal radius) as recorded on the general practice com-
puter records and incident diagnosis of hip fracture.
Fracture risk factors
We examined the following explanatory variables in
ouranalysis,allofwhichareknownorthoughttoaffect
fracture risk and are also likely to be recorded within
the patients’ electronic records as part of routine clin-
ical practice:
 Age at study entry (in single years)
 Body mass index (BMI) (continuous)
18
 Smoking status (non-smoker, former smoker,
light smoker (<10 cigarettes/day), moderate
smoker (10-19 cigarettes/day), heavy smoker
(≥20 cigarettes/day)
19-21
 Townsend deprivation score (with 2001 census
data, evaluated at output area, as a continuous
variable)
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fracture in a first degree relative (binary variable
yes/no)
22
 Diagnosis of cardiovascular disease at baseline
(binary variable yes/no)
12
 Recorded use of alcohol (none, trivial <1 unit/
day, light 1-2 units/day, medium 3-6 units/day,
heavy 7-9 units/day, very heavy >9 units/day)
23
 Diagnosis of rheumatoid arthritis at baseline
(binary variable yes/no)
24
 Diagnosis of type 2 diabetes at baseline (binary
variable yes/no)
25
 Diagnosis of asthma at baseline (binary variable
yes/no)
 History of falls before baseline (binary variable
yes/no)
 Diagnosis of chronic liver disease at baseline
(binary variable yes/no)
 Diagnosis of gastrointestinal conditions likely to
result in malabsorption (such as Crohn’s disease,
ulcerative colitis, coeliac disease, steatorrhoea,
blind loop syndrome) at baseline (binary variable
yes/no)
7
 Diagnosis of other endocrine conditions
(thyrotoxicosis, primary or secondary
hyperparathyroidism, Cushing’s syndrome) at
baseline (binary variable yes/no)
 At least two prescriptions for systemic
corticosteroids in the six months before baseline
(binary variable yes/no)
26
 At least two prescriptions for tricyclic
antidepressants in the six months before baseline
(binary variable yes/no)
14
 At least two prescriptions for HRT (in women) in
the six months before baseline
13
 Menopausal symptoms (in women), including
vaginal dryness or hot flushes (binary variable
yes/no), recorded at baseline.
We restricted all values of these variables to those
that had been recorded in the person’s electronic
healthcare record before baseline, except for BMI
and alcohol and smoking status for which we used the
values recorded closest to study entry date and
recorded before the diagnosis of osteoporotic fracture
(or before censoring for those who did not develop a
fracture). We assumed that if there was no recorded
value of a diagnosis, prescription, or family history
then the patient did not have that exposure.
Model derivation and development
We calculated crude incidence rates of osteoporotic
fracture (hip, vertebral, or distal radius fracture) and
hip fracture by age and sex in the derivation and vali-
dation cohorts. We used Cox’s proportional hazards
models in the derivation dataset to estimate the coeffi-
cients and hazard ratios associated with each potential
risk factor for the first ever recorded diagnosis of over-
all fracture and hip fracture for men and women sepa-
rately. We compared models using the Akaike
informationcriterion(AIC)andtheBayesinformation
criterion (BIC),
27 which are likelihood measures in
which lower values indicate better fit and in which a
penalty is paid for increasing the number of variables
inthemodel.Weusedfractionalpolynomialstomodel
non-linear risk relations with continuous variables
where appropriate.
28 We tested for interactions
between age and smoking; age and parental history
of osteoporosis; age and BMI; age and falls; age and
use of HRT; use of HRT and smoking; and use of
HRT and deprivation. We included significant inter-
actions in the final model when they improved the
model fit based on the AIC. Continuous variables
werecentredforanalysis.Wecheckedtheassumptions
of the proportional hazards model for each variable
graphically using log−log survival plots.
After conducting a complete case analysis, we used
multiple imputation to replace missing values for alco-
hol, smoking status, and BMI, and used these values in
our main analyses.
29-32 We used the ICE procedure in
Stata
33 to obtain five imputed datasets. Our final model
was fitted based on multiply imputed datasets using
Rubin’s rules to combine effect estimates and estimate
standard errors to allow for the uncertainty because of
missing data. Multiple imputation is a statistical techni-
quedesignedtoreducethebiasesthatcanoccurin“com-
pletecase”analysisalongwithasubstantiallossofpower
and precision.
293234 The imputation technique involves
creatingmultiplecopiesofthedataandreplacesmissing
values with imputed values based on a suitable random
samplefromtheirpredicteddistribution.Multipleimpu-
tation therefore allows patients with incomplete data to
still be included in analyses, thereby making full use of
all the available data, thus increasing power and preci-
sion but without compromising validity.
35
We took the regression coefficient (that is, the log of
thehazardratio)foreachvariablefromthefinalmodel
using multiply imputed data and used these as weights
fortheQFractureScores.Asinpreviousstudies,
1036we
combined these weights with the baseline survivor
function for diagnosis of fracture or hip fracture
obtained from the Cox model evaluated at 10 years
and centred on the means of continuous risk factors
to derive a risk equation for 10 years’ follow-up.
Inwomenwedeterminedthehazardratiosforosteo-
porotic fracture overall and for hip fracture by HRT
use at baseline categorised by (unopposed, cyclical,
or continuous) oestrogen dose (high v low dose) and
type of oestrogen (equine v non-equine). These results
were incorporatedin the QFractureScores forwomen.
In a separate analysis, we used a time varying Cox
regressionanalysistoexaminetheeffectsofdurationof
use of HRT and time since stopping HRT on risk of
fractureinwomen,treatingthesetermsastimevarying
covariates. For duration of use of HRT we analysed
non-users and new users to determine the hazard
ratio of each fracture outcome within one year, two to
four years, five to nine years, and 10 years or more of
taking HRT compared with no HRT use. We also
determined change in risks after stopping HRT cate-
gorised as within a year of stopping, one to two years,
two to five years, and five or more years. The date of
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of the last recorded prescription.
Validation of the QFractureScores
We tested the performances of the final models (QFrac-
tureScores) in the validation dataset. We calculated the
10yearestimatedriskofsustainingafractureorhipfrac-
tureforeachpatientinthevalidationdatasetusingmulti-
ple imputation to replace missing values for alcohol,
smoking status, and BMI, as in the derivation dataset.
We calculated the mean predicted fracture risk and
the observed fracture risk at 10 years
36 and compared
these by 10th of predicted risk. The observed risk at
10 years was obtained by using the 10 year Kaplan-
Meier estimate. We calculated the D statistic (a mea-
sure of discrimination where higher values indicate
better discrimination)
37 and an R
2 statistic (which is a
measureofexplainedvariationforsurvivaldata,where
higher values indicate more variation is explained).
38
We also calculated the area under the receiver operat-
ing characteristics (ROC) curve at 10 years, where
higher values indicate better discrimination.
Validation against FRAX (fracture risk assessment)
Wecomparedtheperformanceofthe QFractureScore
in predicting risk of hip fracture with the performance
of the FRAX algorithm using the above validation
statistics. FRAX is a relatively new algorithm that pre-
dicts 10 year absolute risk of hip fracture and osteo-
porotic fracture.
7 It is not currently in widespread use
in primary care in the United Kingdom. We used the
version that does not incorporate bone mineral den-
sity. This version of FRAX is based on the following
variables;
 Age
 Sex
 Height
 Weight
 Previous fracture
 Parental history of hip fracture
 Current smoking
 Glucocorticoid treatment
 Rheumatoid arthritis
 Secondary osteoporosis
 Use of alcohol (>3 units/day).
Table 1 |Characteristics of patients aged 30-85 free of fracture at baseline in derivation and validation cohorts 1993-2008.
Figures are numbers (percentage) unless stated otherwise
Derivation cohort Validation cohort
Women (n=1 183 663) Men (n=1 174 232) Women (n=642 153) Men (n=633 764)
Mean (SD) Townsend score −0.31 (3.47) −0.20 (−3.55) −0.32 (3.33) −0.23 (3.39)
Median (IQR) age 48 (37-62) 46 (37-59) 49 (37-63) 46 (37-69)
Alcohol consumption:
Recorded 801 600 (67.72) 717 616 (61.60) 435 452 (67.81) 391 290 (61.74)
Non-drinker 275 984 (23.32) 140 925 (12.00) 148 646 (23.15) 74 718 (11.79)
Trivial <1unit/day 341 295 (28.83) 226 118 (19.26) 185 570 (28.90) 120 989 (19.09)
Light 1-2 units/day 162 433 (13.72) 234 460 (19.97) 89 435 (13.93) 130 813 (20.64)
Moderate 3-6 units/day 19 455 (1.64) 96 202 (8.19) 10,610 (1.65) 54 239 (8.56)
Heavy 7-9 units/day 1208 (0.10) 11 006 (0.94) 618 (0.10) 6005 (0.95)
Very heavy >9 units/day 1231 (0.10) 8877 (0.76) 616 (0.10) 4567 (0.72)
BMI recorded 884 523 (74.73) 781 619 (66.56) 482 194 (75.09) 431 994 (68.16)
Mean (SD) BMI 25.88 (4.86) 26.43 (4.08) 25.82 (4.85) 26.41 (4.02)
Smoking:
Recorded 1 007 963 (85.16) 929 457 (78.28) 547 531 (85.26) 502 739 (79.33)
Non-smoker 630 470 (53.26) 462 344 (38.94) 340 811 (53.07) 250 715 (39.56)
Ex-smoker 139 496 (11.79) 173 503 (14.61) 75 629 (11.78) 95 004 (14.99)
Current smoker: light 51 945 (4.39) 69 504 (5.85) 29 288 (4.56) 38 173 (6.02)
Current smoker: moderate 131 563 (11.11) 146 959 (12.38) 71 638 (11.16) 76 908 (12.14)
Current smoker: heavy 54 489 (4.60) 77 147 (6.50) 30 165 (4.70) 41 939 (6.62)
Rheumatoid arthritis 9 459 (0.80) 3 903 (0.33) 5 013 (0.78) 2114 (0.33)
Cardiovascular disease 41 842 (3.53) 62 265 (5.24) 23 375 (3.64) 33 542 (5.29)
Type 2 diabetes 22 645 (1.91) 27 637 (2.33) 11 919 (1.86) 14 257 (2.25)
Asthma 66 892 (5.65) 55 888 (4.71) 35 081 (5.46) 28 992 (4.57)
Current tricyclic antidepressants 46 054 (3.89) 14 646 (1.23) 23 729 (3.70) 7354 (1.16)
Current corticosteroids 20 005 (1.69) 11 569 (0.97) 10 509 (1.64) 5792 (0.91)
History of falls 8801 (0.74) 4676 (0.39) 2180 (0.34) 3036 (0.48)
Chronic liver disease 1563 (0.13) 2133 (0.18) 809 (0.13) 1205 (0.19)
Gastrointestinal malabsorption 5970 (0.50) 4851 (0.41) 3346 (0.52) 2595 (0.41)
Other endocrine conditions 8615 (0.73) 1886 (0.16) 5039 (0.78) 1044 (0.16)
Menopausal symptoms 25 683 (2.17) NA 11 830 (1.84) NA
Parental history of osteoporosis 5831 (0.49) 441 (0.04) 2180 0.34) 128 (0.02)
IQR=interquartile range; BMI=body mass index; NA= not applicable.
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fracture outcome as this is directly comparable
between both scores, whereas the FRAX fracture out-
comealsoincludeshumerusfractures.WeusedtheUK
version of the score from the FRAX website (www.
shef.ac.uk/FRAX/index.htm) to calculate the 10 year
predictedriskofhipfractureforallpatientsaged40-85
in the validation dataset, based on relevant input vari-
ables of age, sex, height, weight, parent had fractured
hip (yes/no), current smoking (yes/no), glucocorti-
coids (yes/no), rheumatoid arthritis (yes/no), second-
ary osteoporosis (yes/no), and alcohol >3 units/day
(yes/no). Secondary osteoporosis was defined as hav-
ing liver disease, malabsorption, or endocrine disor-
ders. In all cases previous fracture was counted as
negativeaswerestrictedourcohorttopatientswithout
a previous fracture. We used the same multiply
imputed data that replaced missing values for alcohol
use, smoking status, and BMI to calculate the FRAX
scores as we used in the validation for the QFracture-
Scores. As with the QFractureScores we assumed that
if there was no recorded value of a diagnosis, prescrip-
tion,orfamilyhistorythenthepatientdidnothavethat
exposure. We entered the variables for each patient
twice, in random order, using automated software to
test the reproducibility of the scores generated by the
FRAX website.
As we used all the available data on the QResearch
database we did not calculate sample size before the
study. All analyses were conducted with Stata (version
10).Wechoseasignificancelevelof0.01(twotailed)as
we were considering several variables as potential risk
factors in a large dataset and wanted to reduce the risk
of having an overly complex model including vari-
ables with limited prognostic value.
RESULTS
Description of the derivation and validation dataset
Overall, 535 practices in England and Wales met our
inclusion criteria, of which 357 were randomly
assigned to the derivation dataset and 178 to the vali-
dation dataset.
In the derivation cohort there were 1204222
women (1187354 men) aged 30-85 at baseline, of
whom 20559 (13122) had a recorded fracture before
thestartofthestudyandwerethereforeexcluded,leav-
ing1183663(1174232)freeoffractureatbaselinefor
analysis.
In the validation cohort there were 653789 women
(640943 men) aged 30-85 at baseline, of whom 11636
(7179) had a fracture before the start of the study and
were therefore excluded, leaving 642153 (633764)
free of fracture at baseline for analysis.
Table 1 compares the key characteristics of eligible
patients in each cohort. While this validation cohort
was drawn from an independent group of practices,
the baseline characteristics were similar to those for
Table 2 |Incidence rates of osteoporotic fracture (distal radius, hip, or vertebral) and hip fracture per 1000 person years in derivation and validation cohorts
by age at baseline in men and women
Age (years)
Derivation cohort Validation cohort
Osteoporotic fractures Hip fractures Osteoporotic fractures Hip fractures
No Rate/1000 (95% CI) No Rate/1000(95%CI) No Rate/1000 (95% CI) No Rate/1000 (95% CI)
Women
Total 24 350 3.08 (3.04 to 3.12) 9302 1.15 (1.13 to 1.17) 13 952 3.17 (3.11 to 3.22) 5424 1.2 (1.17 to 1.23)
30-34 605 0.50 (0.46 to 0.54) 23 0.02 (0.01 to 0.03) 322 0.48 (0.43 to 0.54) 8 0.01 (0.01 to 0.02)
35-39 639 0.62 (0.57 to 0.66) 37 0.04 (0.03 to 0.05) 356 0.63 (0.57 to 0.70) 22 0.04 (0.03 to 0.06)
40-44 720 0.88 (0.82 to 0.95) 72 0.09 (0.07 to 0.11) 377 0.83 (0.75 to 0.92) 32 0.07 (0.05 to 0.10)
45-49 1145 1.32 (1.25 to 1.40) 140 0.16 (0.14 to 0.19) 637 1.31 (1.21 to 1.42) 70 0.14 (0.11 to 0.18)
50-54 1745 1.97 (1.88 to 2.07) 229 0.25 (0.22 to 0.29) 941 1.89 (1.77 to 2.01) 129 0.25 (0.21 to 0.30)
55-59 1951 2.70 (2.58 to 2.82) 326 0.44 (0.39 to 0.49) 1156 2.83 (2.67 to 3.00) 220 0.53 (0.46 to 0.60)
60-64 2578 3.99 (3.84 to 4.15) 615 0.92 (0.85 to 1.00) 1451 4.03 (3.83 to 4.24) 407 1.09 (0.99 to 1.20)
65-69 3282 5.72 (5.53 to 5.92) 1152 1.92 (1.81 to 2.04) 1888 5.81 (5.56 to 6.08) 677 1.99 (1.85 to 2.15)
70-74 4086 8.05 (7.81 to 8.30) 1899 3.55 (3.39 to 3.71) 2378 8.35 (8.02 to 8.69) 1085 3.59 (3.39 to 3.81)
75-85 7599 12.11 (11.84 to 12.38) 4809 7.19 (6.99 to 7.40) 4446 12.39 (12.04 to 12.76) 2774 7.23 (6.97 to 7.51)
Men
Total 7934 0.99 (0.96 to 1.01) 3067 0.38 (0.36 to 0.39) 4519 1.01 (0.98 to 1.04) 1738 0.38 (0.37 to 0.40)
30-34 693 0.54 (0.50 to 0.58) 46 0.04 (0.03 to 0.05) 344 0.49 (0.44 to 0.54) 26 0.04 (0.02 to 0.05)
35-39 677 0.57 (0.53 to 0.61) 58 0.05 (0.04 to 0.06) 354 0.54 (0.48 to 0.60) 38 0.06 (0.04 to 0.08)
40-44 592 0.57 (0.53 to 0.62) 88 0.08 (0.07 to 0.10) 339 0.58 (0.52 to 0.64) 40 0.07 (0.05 to 0.09)
45-49 610 0.61 (0.56 to 0.66) 109 0.11 (0.09 to 0.13) 353 0.63 (0.56 to 0.70) 60 0.11 (0.08 to 0.14)
50-54 629 0.72 (0.67 to 0.78) 135 0.15 (0.13 to 0.18) 354 0.73 (0.66 to 0.81) 76 0.16 (0.12 to 0.19)
55-59 629 0.87 (0.80 to 0.94) 189 0.26 (0.22 to 0.30) 381 0.94 (0.85 to 1.04) 104 0.25 (0.21 to 0.31)
60-64 661 1.06 (0.98 to 1.14) 251 0.4 (0.35 to 0.45) 375 1.09 (0.98 to 1.20) 148 0.42 (0.36 to 0.50)
65-69 787 1.49 (1.39 to 1.60) 398 0.75 (0.68 to 0.82) 461 1.60 (1.46 to 1.75) 237 0.81 (0.71 to 0.92)
70-74 1014 2.54 (2.39 to 2.70) 599 1.48 (1.37 to 1.61) 603 2.72 (2.51 to 2.94) 355 1.58 (1.42 to 1.75)
75-85 1642 4.35 (4.15 to 4.57) 1194 3.13 (2.95 to 3.31) 955 4.51 (4.23 to 4.80) 654 3.05 (2.82 to 3.29)
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and women.
Table 2 shows the incidence rates in each cohort.
During the 7898208 person years of follow-up for
women in the derivation cohort 24350 fractures were
recorded (hip, vertebral, or distal radius), giving an
overall incidence rate of 3.08 per 1000 person years
(95% confidence interval 3.04 to 3.12). For men,
there were 7934 incident fractures arising from
8049306 person years, giving an incidence rate of
0.99 per 1000 person years (0.96 to 1.01). In women,
38.2% of the fractures were hip fractures, in men the
corresponding figure was 38.9%. Similar incidence
rateswerefoundinthevalidationcohort(table2).Inci-
dence rates were higher in women than in men and
rose steeply with age. In the derivation cohort, highest
fracture rates were observed among those aged 75 and
over at baseline:the incidence ratewas12.11per 1000
person years (11.84 to 12.38) in women and 4.35 per
1000 person years (4.15 to 4.57) in men. The corre-
sponding figures for incidence of hip fracture among
those aged 75 and over were 7.19 per 1000 person
years(6.99to7.40)inwomenand3.13per1000person
years (2.95 to 3.31) in men.
Tables 3 and 4 show the characteristics of patients
with and without BMI, smoking status, and alcohol
Table 3 |Characteristics of patients with and without body mass index (BMI) and with and without smoking status recorded.
Figures are numbers (percentage) unless stated otherwise
Women Men
According to BMI recording
BMI recorded Yes No Yes No
Total 870 874 312 789 781 619 392 613
Mean (SD) age (years) 49.34 (14.17) 54.87 (17.70) 48.15 (13.41) 50.38 (15.87)
Mean (SD) Townsend −0.45 (3.43) 0.06 (3.55) −0.35 (3.51) 0.11 (3.62)
Current smoker 210 541 (24.18) 39 090 (12.50) 246 484 (31.54) 56 324 (14.35)
Parental history of osteoporosis 5377 (0.62) 454 (0.15) 396 (0.05) 45 (0.01)
Rheumatoid arthritis 6703 (0.77) 2756 (0.88) 2605 (0.33) 1298 (0.33)
Cardiovascular disease 6575 (0.75) 35 267 (11.28) 7616 (0.97) 54 649 (13.92)
Type 2 diabetes 16 589 (1.90) 6056 (1.94) 19 732 (2.52) 7905 (2.01)
Asthma 55 049 (6.32) 11 843 (3.79) 43 678 (5.59) 12 210 (3.11)
Current tricyclic antidepressants 35 835 (4.11) 10 219 (3.27) 10 272 (1.31) 4374 (1.11)
Current corticosteroids 15 139 (1.74) 4866 (1.56) 8042 (1.03) 3527 (0.90)
History of falls 5741 (0.66) 3060 (0.98) 2809 (0.36) 1867 (0.48)
Chronic liver disease 1090 (0.13) 473 (0.15) 1424 (0.18) 709 (0.18)
Gastrointestinal malabsorption 4814 (0.55) 1156 (0.37) 3582 (0.46) 1269 (0.32)
Other endocrine conditions 6549 (0.75) 2066 (0.66) 1336 (0.17) 550 (0.14)
Menopausal symptoms 21 889 (2.51) 3794 (1.21) NA NA
10 year osteoporotic fracture risk 2.62 4.30 0.9 1.12
10 year hip fracture risk 0.81 2.19 0.29 0.56
According to smoking recording
Smoking recorded Yes No Yes No
Total 1 007 963 175 700 929 457 244 775
Mean (SD) age (years) 49.67 (14.53) 57.3 (18.26) 48.24 (13.62) 51.39 (16.49)
Mean (SD) Townsend −0.41 (3.45) 0.23 (3.57) −0.32 (3.52) 0.29 (3.63)
Current smoker 249 631 (24.77) 0 (0.00) 302 808 (32.58) 0 (0.00)
Parental history of osteoporosis 5719 (0.57) 112 (0.06) 422 (0.05) 19 (0.01)
Rheumatoid arthritis 8021 (0.80) 1438 (0.82) 3136 (0.34) 767 (0.31)
Cardiovascular disease 11 437 (1.13) 30 405 (17.31) 18 525 (1.99) 43 740 (17.87)
Type 2 diabetes 18 359 (1.82) 4286 (2.44) 21733 (2.34) 5904 (2.41)
Asthma 61 741 (6.13) 5151 (2.93) 49 987 (5.38) 5901 (2.41)
Current tricyclic antidepressants 40 834 (4.05) 5220 (2.97) 12 169 (1.31) 2477 (1.01)
Current corticosteroids 17 476 (1.73) 2529 (1.44) 9683 (1.04) 1886 (0.77)
History of falls 7104 (0.70) 1697 (0.97) 3621 (0.39) 1055 (0.43)
Chronic liver disease 1310 (0.13) 253 (0.14) 1715 (0.18) 418 (0.17)
Gastrointestinal malabsorption 5428 (0.54) 542 (0.31) 4201 (0.45) 650 (0.27)
Other endocrine conditions 7507 (0.74) 1108 (0.63) 1542 (0.17) 344 (0.14)
Menopausal symptoms 24 226 (2.40) 1457 (0.83) NA NA
10 year osteoporotic fracture risk 2.78 4.88 0.94 1.07
10 year hip fracture risk 0.93 2.71 0.58 0.33
NA=not applicable.
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of patients with complete data for all three variables.
There were differences in observed characteristics
betweenthose withand withoutmissingdata, support-
ing the assumption that data are missing at random,
which supports the use of multiple imputation.
Model development
Table 5 shows the results of the multivariate final Cox
regression analysis for fracture and hip fracture in men
based on a complete cases analysis and using multiply
imputed data. Table 6 shows the results for women.
There was no evidence that the proportional hazards
assumptionwasnotvalidinanyofthemodelspresented.
Risk factors for fracture in men
After adjustment for all other variables in the model,
we found significant associations with overall risk of
fracture and risk of hip fracture in men for the follow-
ing variables, which were therefore included in both
final algorithms for men: age, BMI, smoking status,
alcohol use, rheumatoid arthritis, cardiovascular dis-
ease, type 2 diabetes, asthma, use of tricyclic anti-
depressants, history of falls, and liver disease. For
Table 4 |Characteristics of patients with and without alcohol status recorded and with and without complete data for body
mass index (BMI), smoking status, and alcohol status. Figures are numbers (percentage) unless stated otherwise
Women Men
According to alcohol recording
Alcohol recorded Yes No Yes No
Total 801 606 382 057 717 588 456 644
Mean (SD) age (years) 49.63 (14.20) 53.26 (17.35) 48.25 (13.30) 49.91 (15.74)
Mean (SD) Townsend −0.46 (3.43) −0.01 (3.54) −0.39 (3.50) 0.11 (3.61)
Current smoker 194 143 (24.22) 55 488 (14.52) 227 718 (31.73) 75 090 (16.44)
Parental history of osteoporosis 5284 (0.66) 547 (0.14) 400 (0.06) 41 (0.01)
Rheumatoid arthritis 6544 (0.82) 2915 (0.76) 2516 (0.35) 1387 (0.30)
Cardiovascular disease 6439 (0.80) 35 403 (9.27) 7545 (1.05) 54 720 (11.98)
Type 2 diabetes 15 618 (1.95) 7027 (1.84) 18 201 (2.54) 9436 (2.07)
Asthma 50 654 (6.32) 16 238 (4.25) 39 318 (5.48) 16 570 (3.63)
Current tricyclic antidepressants 33 865 (4.22) 12 189 (3.19) 9659 (1.35) 4987 (1.09)
Current corticosteroids 13 909 (1.74) 6096 (1.60) 7236 (1.01) 4333 (0.95)
History of falls 5765 (0.72) 3036 (0.79) 2858 (0.40) 1818 (0.40)
Chronic liver disease 1051 (0.13) 512 (0.13) 1410 (0.20) 723 (0.16)
Gastrointestinal malabsorption 4506 (0.56) 1464 (0.38) 3395 (0.47) 1456 (0.32)
Other endocrine conditions 6231 (0.78) 2384 (0.62) 1275 (0.18) 611 (0.13)
Menopausal symptoms 21 159 (2.64) 4524 (1.18) NA NA
10 year osteoporotic fracture risk 2.75 3.68 0.95 0.98
10 year hip fracture risk 0.88 1.79 0.32 0.47
According to completeness of data
Complete data Yes No Yes No
Total 732 931 450 732 649 500 524 732
Mean (SD) age (years) 49.42 (13.94) 53.06 (17.24) 48.27 (13.17) 49.67 (15.59)
Mean (SD) Townsend −0.5 (3.42) −0.01 (3.54) −0.42 (3.49) 0.08 (3.61)
10 year fracture risk 0.9737 0.9621 0.9908 0.9897
Current smoker 177 512 (24.22) 72 119 (16.00) 204 667 (31.51) 98 141 (18.70)
Parental history of osteoporosis 5071 (0.69) 760 (0.17) 387 (0.06) 54 (0.01)
Rheumatoid arthritis 5848 (0.80) 3611 (0.80) 2261 (0.35) 1642 (0.31)
Cardiovascular disease 4802 (0.66) 37 040 (8.22) 5433 (0.84) 56 832 (10.83)
Type 2 diabetes 14 492 (1.98) 8153 (1.81) 17 237 (2.65) 10 400 (1.98)
Asthma 47 202 (6.44) 19 690 (4.37) 36 652 (5.64) 19 236 (3.67)
Current tricyclic antidepressants 31 111 (4.24) 14 943 (3.32) 8721 (1.34) 5925 (1.13)
Current corticosteroids 12 743 (1.74) 7262 (1.61) 6547 (1.01) 5022 (0.96)
History of falls 5077 (0.69) 3724 (0.83) 2467 (0.38) 2209 (0.42)
Chronic liver disease 915 (0.12) 648 (0.14) 1221 (0.19) 912 (0.17)
Gastrointestinal malabsorption 4197 (0.57) 1773 (0.39) 3120 (0.48) 1731 (0.33)
Other endocrine conditions 5741 (0.78) 2874 (0.64) 1180 (0.18) 706 (0.13)
Menopausal symptoms 19 991 (2.73) 5692 (1.26) NA NA
10 year osteoporotic fracture risk 2.63 2.63 0.92 1.03
10 year hip fracture risk 0.79 1.83 0.29 0.50
NA=not applicable.
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teroidsinthefinalmodelsforosteoporoticfractureand
hip fracture, although it tended towards significance
only for hip fracture (P=0.067), which might reflect
thelowernumbersofpatientswithahipfracture.Vari-
ablesthat werenot significantonmultivariate analyses
in men (and that were not therefore included in the
finalalgorithms)includeddeprivation,gastrointestinal
malabsorption,otherendocrineconditions,andparen-
tal history of osteoporosis. There were also no signifi-
cant interactions.
Table5showstheadjustedhazardratiosforthevari-
ables included in both final algorithms for men based
on the multiply imputed data; fractional polynomial
terms for age and BMI were also included in the algo-
rithms. Patients with liver disease had a 196%
increased risk of hip fracture after adjustment for all
other variables. Similarly, patients with a history of
falls had a 166% increased risk of hip fracture. Heavy
smokers had a 70% increased risk of hip fracture com-
pared with non-smokers; patients with very heavy
alcohol intake had a 70% increased risk compared
with non-drinkers. Compared with patients without
each disease, patients with rheumatoid arthritis had
an81%increasedriskofhipfracture;thosewithcardio-
vascular disease had a 24% increased risk; those with
type 2 diabetes had a 38% increased risk; and those
with asthma had a 31% increased risk. Patients taking
tricyclic antidepressants had a 67% increased risk of
hip fracture, and those prescribed steroids had a 22%
increased risk.
Figure 1 shows the estimated adjusted hazard ratios
with the fractional polynomial terms for age and BMI
in men. There were two age terms for the osteoporotic
fracture outcome (age/10) and (age/10)
2 and one term
forBMI(bmi/10)
−2.Therewasasingleagetermforhip
fracture, which was (age/10)
2 with two terms for BMI:
log(BMI/10) and (log(BMI/10))
2.
Risk factors for fracture in women
After adjustment for all other variables in themodel, we
foundsignificantassociationswithoverallfractureriskin
womenforthefollowingvariables:useofHRT,smoking
status, use of alcohol, parental history of osteoporosis,
rheumatoid arthritis, cardiovascular disease, type 2 dia-
betes, asthma, tricyclic antidepressants, use of corticos-
teroids, history of falls, menopausal symptoms, chronic
liver disease, gastrointestinal malabsorption, and other
endocrine disorders (table 6). There were also signifi-
cant associations withage and BMI with fractional poly-
nomial terms. The final algorithm for osteoporotic
fractureinwomenincludedallofthesevariables.Table 6
shows the adjusted hazard ratios.
Some variables were significantly associated with
overall risk of fracture but not with risk of hip fracture
at the 0.01 level. These were use of HRT, menopausal
Table 5 |Adjusted hazard ratios* (95% confidence intervals) for osteoporotic fracture (distal radius, hip, or vertebral) and hip
fracture in men
Osteoporotic fracture Hip fracture
Complete case analysis Multiply imputed data Complete case analysis Multiply imputed data
Non-smoker 1.00 1.00 1.00 1.00
Ex-smoker 0.98 (0.91 to 1.05) 0.98 (0.92 to 1.05) 0.99 (0.87 to 1.11) 0.99 (0.89 to 1.10)
Current smoker:
Light 1.06 (0.95 to 1.17) 1.13 (1.03 to 1.23) 1.23 (1.03 to 1.46) 1.21 (1.05 to 1.40)
Moderate 1.24 (1.13 to 1.36) 1.20 (1.12 to 1.29) 1.61 (1.37 to 1.91) 1.47 (1.26 to 1.71)
Heavy 1.4 (1.27 to 1.55) 1.36 (1.25 to 1.47) 2.18 (1.82 to 2.62) 1.70 (1.44 to 2.00)
Alcohol:
Non-drinker 1.00 1.00 1.00 1.00
Trivial <1unit/day 0.91 (0.84 to 0.99) 0.93 (0.86 to 0.99) 0.81 (0.71 to 0.92) 0.78 (0.71 to 0.87)
Light 1-2 units/day 0.95 (0.88 to 1.03) 0.95 (0.89 to 1.02) 0.84 (0.74 to 0.97) 0.77 (0.70 to 0.86)
Moderate 3-6 units/day 1.08 (0.98 to 1.19) 1.05 (0.95 to 1.16) 0.91 (0.76 to 1.09) 0.81 (0.70 to 0.93)
Heavy 7-9 units/day 1.06 (0.83 to 1.35) 1.10 (0.89 to 1.36) 0.85 (0.52 to 1.38) 0.82 (0.56 to 1.20)
Very heavy >9 units/day 1.84 (1.47 to 2.29) 1.62 (1.34 to 1.96) 2.56 (1.78 to 3.67) 1.70 (1.20 to 2.43)
Rheumatoid arthritis† 1.41 (1.01 to 1.97) 1.48 (1.15 to 1.90) 1.81 (1.15 to 2.85) 1.81 (1.31 to 2.50)
Cardiovascular disease† 1.11 (0.89 to 1.39) 1.29 (1.20 to 1.39) 1.15 (0.84 to 1.58) 1.24 (1.13 to 1.37)
Type 2 diabetes† 1.18 (1.02 to 1.37) 1.20 (1.07 to 1.35) 1.42 (1.15 to 1.74) 1.38 (1.18 to 1.62)
Asthma† 1.24 (1.10 to 1.39) 1.28 (1.17 to 1.41) 1.24 (1.01 to 1.52) 1.31 (1.12 to 1.53)
Current tricyclic
antidepressants†
1.40 (1.18 to 1.67) 1.36 (1.18 to 1.56) 1.77 (1.37 to 2.28) 1.67 (1.38 to 2.01)
Current corticosteroids† 1.65 (1.39 to 1.97) 1.46 (1.27 to 1.68) 1.61 (1.23 to 2.10) 1.22 (0.99 to 1.51)
History of falls† 2.17 (1.60 to 2.93) 2.23 (1.80 to 2.75) 2.29 (1.46 to 3.61) 2.66 (2.03 to 3.49)
Liver disease† 3.59 (2.45 to 5.24) 2.86 (2.04 to 4.01) 3.75 (2.01 to 6.99)_ 2.96 (1.75 to 5.01)
BMI=body mass index.
*Hazard ratios simultaneously adjusted for all other variables shown in table as well as fractional polynomial terms for age and BMI. Fractional
polynomial terms for age and BMI were: (age/10) and (age/10)
2 and (BMI/10)
−2 for osteoporotic fracture; and (age/10)
2 and log(BMI/10) and (log
(BMI/10))
2 for hip fracture.
†Compared with patients without condition/medication at baseline.
RESEARCH
page 8 of 17 BMJ | ONLINE FIRST | bmj.comsymptoms,parentalhistoryofosteoporosis,malabsorp-
tion,andotherendocrinedisorders.Themagnitudeand
direction of the coefficients were similar to those for
overall risk of fracture so they were included in the
final hip fracture model for consistency. The final algo-
rithm for risk of hip fracture in women included age,
BMI,smokingstatus,alcoholuse,use ofHRT,parental
history of osteoporosis, rheumatoid arthritis, cardio-
vascular disease, type 2 diabetes, asthma, current use
of tricyclic antidepressants, current use of corticoster-
oids, history of falls, menopausal symptoms, liver dis-
ease, gastrointestinal malabsorption, and other
endocrinedisorders.Table 6showstheadjustedhazard
ratiosforvariables includedinbothfinalalgorithms for
women based on the multiply imputed data.
Figure 1 shows the estimated adjusted hazard ratios
with the fractional polynomial terms for age and BMI
in women. There were two terms for age for the frac-
ture outcome, these were (age/10)
−1 and (age/10)
−1log
(age/10).Therewasonefractionalpolynomialtermfor
BMI, which was (BMI/10)
−1. The terms selected for
inclusion in the hip fracture model in women were
(age/10)
3 and (age/10)
3log(age/10) and one term for
BMI, which was (BMI/10)
−2.
There were significant interactions between age and
BMI and between age and parental history of osteo-
porosis for overall fracture in women. The more com-
plex model including the age interaction terms,
however, did not improve the model fit statistics and
resulted in similar predicted scores compared with the
simpler model so we selected the more parsimonious
version as our final model.
Effect of hormone replacement therapy on fracture risk
Overall, 168536 women (14.24% of 1183663) were
prescribed HRT at baseline. Of these, 16425 (9.75%)
were prescribed low dose oestrogen equine; 30598
(18.16%) were prescribed low dose non-equine; 7474
(4.43%) were prescribed high dose equine; 7205
(4.28%) were prescribed high dose non-equine; 23430
(13.90%) were prescribed cyclical low equine; 28427
(16.87%)wereprescribedcyclicallowdosenon-equine;
2342 (1.392%) were prescribed cyclical high dose
equine; 16753 (9.94%) were prescribed cyclical high
dose non-equine;6765(4.01%) were prescribedcontin-
uous low dose equine; 11629 (6.90%) were prescribed
continuous low dose non-equine; 14186 (8.42%) were
prescribedcontinuoushighdose non-equine; and3302
(1.96%) were prescribed tibolone.
We found significant associations between risk of
fracture and some types of HRT (table 6). Women
prescribed unopposed oestrogen HRT had a reduced
riskofosteoporoticfracture.Therewasa25%decrease
(8% to 38%) in risk of fracture with high dose unop-
posed equine oestrogen, and a 19% decreased risk
(5% to 30%) for cyclical high dose non-equine, both
of which were significant at the 0.01 level. There was
a borderlinesignificant decrease in risk (0.01<P<0.05)
with low dose unopposed equine oestrogen, low dose
unopposed non-equine oestrogen, high dose unop-
posed non-equine oestrogen, and continuous high
dose non-equine. There was a 24% increase in risk
with continuous low dose equine HRT (6% to 45%).
Thedirectionandthemagnitudeoftherisksassociated
with HRT use for the hip fracture outcome were simi-
lar,althoughtheywere notsignificantatthe0.01level.
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Fig 1 | Adjusted hazard ratios for age (compared with age 30) and BMI (compared with BMI=25) for osteoporotic fracture (distal
radius, hip, or vertebral) and for hip fracture in men and women with fractional polynomial terms
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a borderline association with a 20% decrease in risk
(2% to 34%, P=0.026).
Table7showstheresultsofthetimevaryinganalyses
for duration of use of HRT and time since stopping
HRT.Therewasatrendovertimewithincreasingdura-
tionofuseofHRT,withnosignificanteffectofHRTon
overall risk of fracture in the first year of use, a 36%
significant decrease in risk (8% to 40%) for one to two
years of use, and a 45% decreased risk among women
with10ormoreyearsofuse(16%to64%).Therewasno
significant increase or decrease in risk within the first
year after stopping HRT, although there was a 23%
increase in risk (8% to 42%) one to two years after stop-
ping and a 23% increase (12% to 34%) two to five years
afterstoppingcomparedwithwomenwhohadnotbeen
prescribed HRT. The pattern for the time varying ana-
lysisforthehipfractureoutcomewithdurationofuseof
HRT was similar: the decrease ranged between a 58%
reductioninriskafteronetotwoyearsofuseanda31%
reduction after two to five years. Although the confi-
dence intervalswerewiderbecause ofthe smallernum-
berofincidentcases,therewasnoassociationwithtime
since stopping HRT
Table 6 |Adjusted hazard ratios* (95% confidence intervals) for osteoporotic fractures (distal radius, hip, vertebral) and hip fracture in women
Osteoporotic fracture Hip fracture
Complete case analysis Multiply imputed data Complete case analysis Multiply imputed data
No use of HRT 1.00 1.00 1.00 1.00
Type of HRT†:
Low dose unopposed equine oestrogen 0.91 (0.81 to 1.02) 0.90 (0.81 to 0.99) 0.84 (0.66 to 1.06) 0.80 (0.66 to 0.97)
Low dose unopposed non-equine oestrogen 0.90 (0.82 to 0.99) 0.90 (0.82 to 0.98) 0.96 (0.79 to 1.17) 0.87 (0.74 to 1.03)
High dose unopposed equine oestrogen 0.72 (0.57 to 0.90) 0.75 (0.62 to 0.92) 0.66 (0.37 to 1.16) 0.65 (0.40 to 1.06)
High dose unopposed non-equine oestrogen 0.73 (0.57 to 0.94) 0.76 (0.61 to 0.96) 0.74 (0.40 to 1.38) 0.80 (0.48 to 1.33)
Cyclical low dose equine 0.90 (0.81 to 1.01) 0.92 (0.83 to 1.02) 0.91 (0.68 to 1.21) 0.93 (0.72 to 1.19)
Cyclical low dose non-equine 0.88 (0.78 to 0.99) 0.94 (0.84 to 1.04) 0.78 (0.56 to 1.08) 0.80 (0.60 to 1.07)
Cyclical high dose equine 1.14 (0.81 to 1.60) 1.14 (0.84 to 1.56) 1.06 (0.44 to 2.56) 1.00 (0.45 to 2.23)
Cyclical high dose non-equine 0.79 (0.67 to 0.93) 0.81 (0.70 to 0.94) 0.93 (0.61 to 1.42) 0.91 (0.62 to 1.33)
Continuous low dose equine 1.16 (0.96 to 1.39) 1.24 (1.06 to 1.45) 1.20 (0.82 to 1.77) 1.12 (0.80 to 1.56)
Continuous low dose non-equine 0.97 (0.83 to 1.14) 1.03 (0.89 to 1.19) 0.87 (0.59 to 1.30) 0.84 (0.59 to 1.20)
Continuous high dose non-equine 0.82 (0.72 to 0.93) 0.88 (0.78 to 0.99) 0.73 (0.54 to 1.00) 0.82 (0.64 to 1.06)
Tibolone 0.86 (0.67 to 1.10) 0.92 (0.74 to 1.14) 0.41 (0.19 to 0.86) 0.62 (0.37 to 1.03)
Non-smoker 1.00 1.00 1.00 1.00
Ex-smoker 1.02 (0.97 to 1.06) 1.02 (0.98 to 1.06) 1.05 (0.97 to 1.14) 1.04 (0.97 to 1.11)
Current smoker:
Light 1.02 (0.95 to 1.10) 1.04 (0.98 to 1.11) 1.21 (1.06 to 1.37) 1.18 (1.05 to 1.32)
Moderate 1.14 (1.07 to 1.20) 1.11 (1.06 to 1.17) 1.42 (1.28 to 1.58) 1.32 (1.22 to 1.43)
Heavy 1.21 (1.12 to 1.31) 1.21 (1.13 to 1.29) 1.87 (1.62 to 2.16) 1.55 (1.39 to 1.73)
Alcohol:
Non-drinker 1.00 1.00 1.00 1.00
Trivial <1units/day 1.00 (0.97 to 1.04) 1.00 (0.97 to 1.03) 0.92 (0.86 to 0.97) 0.88 (0.82 to 0.94)
Light 1-2 units/day 1.04 (0.99 to 1.09) 1.02 (0.97 to 1.07) 0.91 (0.84 to 0.99) 0.87 (0.81 to 0.94)
Moderate 3-6 units/day 1.08 (0.96 to 1.21) 1.03 (0.92 to 1.14) 1.10 (0.89 to 1.35) 0.95 (0.77 to 1.18)
Heavy 7-9 units/day 1.58 (1.06 to 2.36) 1.48 (1.06 to 2.06) 1.60 (0.76 to 3.35) 1.41 (0.81 to 2.45)
Very heavy >9 units/day 2.40 (1.66 to 3.46) 2.01 (1.49 to 2.71) 2.93 (1.57 to 5.47) 2.25 (1.35 to 3.73)
Parental history osteoporosis† 1.63 (1.38 to 1.92) 1.78 (1.54 to 2.07) 1.09 (0.69 to 1.71) 1.06 (0.71 to 1.58)
Rheumatoid arthritis† 1.26 (1.11 to 1.43) 1.31 (1.18 to 1.44) 1.82 (1.52 to 2.18) 1.78 (1.56 to 2.03)
Cardiovascular disease† 1.12 (0.99 to 1.28) 1.17 (1.12 to 1.22) 1.26 (1.04 to 1.52) 1.17 (1.09 to 1.24)
Type 2 diabetes† 1.27 (1.17 to 1.39) 1.25 (1.17 to 1.34) 1.79 (1.59 to 2.02) 1.67 (1.51 to 1.83)
Asthma† 1.28 (1.20 to 1.36) 1.29 (1.22 to 1.36) 1.39 (1.24 to 1.55) 1.32 (1.21 to 1.44)
Current tricyclic antidepressants† 1.29 (1.21 to 1.37) 1.31 (1.25 to 1.38) 1.31 (1.18 to 1.46) 1.34 (1.24 to 1.45)
Current corticosteroids† 1.17 (1.07 to 1.28) 1.17 (1.09 to 1.26) 1.13 (0.97 to 1.31) 1.18 (1.05 to 1.31)
History of falls† 1.65 (1.45 to 1.87) 1.82 (1.66 to 1.99) 1.69 (1.40 to 2.05) 2.03 (1.80 to 2.29)
Menopausal symptoms† 1.13 (1.03 to 1.23) 1.15 (1.07 to 1.24) 1.16 (0.99 to 1.36) 1.13 (0.99 to 1.28)
Liver disease† 1.79 (1.30 to 2.46) 1.79 (1.41 to 2.27) 1.75 (1.02 to 3.02) 1.65 (1.13 to 2.42)
Gastrointestinal malabsorption† 1.32 (1.11 to 1.57) 1.23 (1.06 to 1.43) 1.29 (0.94 to 1.76) 1.10 (0.85 to 1.42)
Other endocrine disorder† 1.10 (0.95 to 1.26) 1.11 (1.00 to 1.25) 1.09 (0.69 to 1.71) 1.19 (1.01 to 1.40)
BMI=body mass index; HRT= hormone replacement therapy.
*Hazard ratios simultaneously adjusted for all variables shown in table as well as fractional polynomial terms for age and BMI. Fractional polynomial terms for age and BMI were: (age/10)
−1
and (age/10)
−1log(age/10) and (BMI/10)
−1 for osteoporotic fracture; and (age/10)
3 and (age/10)
3log(age/10) and (BMI/10)
−2 for hip fracture.
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Discrimination
Table 8 shows the discrimination statistics for the
QFractureScoresformenandwomenforbothfracture
outcomes.Thehipfracturealgorithmhadthebestper-
formance among both men and women. It explained
63.94% (62.12% to 65.76%) of the variation in women
and 63.19% (60.81% to 65.57%) of the variation in
men. The D statistic values were high for women
(2.73, 2.62 to 2.83) and men (2.68, 2.55 to 2.82) and
were over twice the magnitude of the corresponding
D statistic results for osteoporotic fracture in men and
women. The ROC values for hip fracture were high
with values of 0.89 for women and 0.86 for men com-
pared with 0.79 and 0.69, respectively, for the overall
fracture outcome.
Calibration
Table 9 compares the mean predicted scores applying
the QFractureScores with the observed risks at
10 years within each 10th of predicted risk to assess
the calibration of the model in the validation sample.
There was close correspondence between predicted
and observed 10 year risks within each model 10th
for overall fracture. For example, in the top 10th of
risk, the mean predicted 10 year risk of fracture was
12.9% and the observed risk was 13.0%. The ratio of
predicted to observed risk in this 10th was 0.99, indi-
cating almost perfect calibration (a ratio of 1 indicates
perfect calibration—that is, no underprediction or
overprediction). Similar results were obtained for
men with a ratio of 1.0 in the top 10th of predicted
risk. For hip fracture there was also close correspon-
dence, except for overprediction in the lowest 10th in
both sexes and the third lowest in women. There was
also 19% overprediction of risk among the top 10th of
predicted risk for hip fracture in men, with 4% over-
prediction for women.
Table 9 also shows the decile cut-offs for men and
women for each of the QFractureScores and the num-
ber and proportion of incident cases in each 10th. For
women for the fracture outcome, 33.72% of incident
cases fell in the top 10th and 31.89% for men. For
womenforthehipfractureoutcome,52.69%ofincident
cases fell in the top 10th and 54.20% of cases for men.
Validation of the fracture clinical risk score against FRAX
WecalculatedahipfracturescoreusingtheFRAXalgo-
rithm for 454499 women aged 40-85 and 424336 men
in the validation cohort. The D statistic for hip fracture
for the FRAX algorithm was 2.26 (2.21 to 2.30) for
women and 2.22 (2.14 to 2.30) for men. The FRAX
algorithm explained 54.83% (54.43% to 55.12%) of the
variation in women and 54.07% (52.10% to 53.65%) in
men. The ROC value for the FRAX algorithm was
0.845 for women and 0.817 for men.
We recalculated the validation statistics for the
QFractureScores restricting the population to patients
aged 40-85. The D statistic for hip fracture was 2.37
(2.32 to 2.42) for women and 2.39 (2.30 to 2.48) for
men. The QFractureScores algorithm explained
57.29% (57.18% to 58.09%) of the variation in
women and 57.67% (56.78% to 58.57%) in men.
Table10andfigure2showthecalibrationstatisticsfor
patients aged 40-85. FRAX tended to overpredict the
risk of hip fracture within each 10th of risk, as shown
by the ratio of the predicted risk to the observed risk.
DISCUSSION
Summary of main findings
A new risk prediction algorithm (the QFractureScore)
for estimating the 10 year absolute risk of osteoporotic
fracture and hip fracture in men and women shows
some evidence of improved discrimination and cali-
bration compared with the FRAX algorithm. We
addressed some of research questions highlighted by
NICE guidance,
6 National Osteoporosis Guidelines,
5
and the WHO.
11 Our algorithm extends the age
range and quantifies additional risk factors not fully
taken account of in FRAX, such as falls, type 2 dia-
betes,cardiovasculardisease,useofHRT,menopausal
symptoms, and use of tricyclic antidepressants. We
also validated the QFractureScores algorithms
Table 7 |Risk of osteoporotic fractures and hip fracture for duration of use of HRT and time
since stopped HRT in women from time varying covariate analysis. Figures are adjusted
hazard ratios* (95% confidence intervals)
Osteoporotic fracture Hip fracture
HR (95% CI) P value HR (95% CI) P value
Not taking HRT 1.00 1.00
Taking HRT:
1 year 0.86 (0.73 to 1.02) 0.08 0.73 (0.51 to 1.06) 0.09
1-2 years 0.74 (0.60 to 0.92) 0.006 0.41 (0.22 to 0.80) 0.01
2-5 years 0.70 (0.61 to 0.81) <0.001 0.69 (0.49 to 0.99) 0.04
5-9 years 0.70 (0.59 to 0.82) <0.001 0.83 (0.58 to 1.17) 0.28
≥10 years 0.55 (0.36 to 0.84) 0.006 0.73 (0.33 to 1.63) 0.44
Stopped HRT:
<1 year 1.07 (0.93 to 1.23) 0.36 1.09 (0.81 to 1.46) 0.58
1-2 years 1.23 (1.08 to 1.42) 0.003 0.96 (0.69 to 1.32) 0.78
2-5 years 1.23 (1.12 to 1.34) <0.001 1.05 (0.87 to 1.28) 0.61
≥5 years 1.12 (1.01 to 1.24) 0.03 0.96 (0.79 to 1.18) 0.69
HRT= hormone replacement therapy.
*Hazard ratios adjusted for variables included in final models for osteoporotic fracture and hip fracture in
women as shown in table 3.
Table 8 |Validation statistics* for QFractureScore for
osteoporotic fracture and hip fracture in validation cohort.
Figures are means (95% confidence intervals)
Osteoporotic fracture Hip fracture
Women
R
2 44.87 (43.07 to 46.67) 63.94 (62.12 to65.76)
D statistic 1.85 (1.78 to 1.91) 2.73 (2.62 to 2.83)
ROC statistic 0.788 (0.786 to 0.790) 0.890 (0.889 to0.892)
Men
R
2 30.02 (22.21 to 37.84) 63.19 (60.81 to65.57)
D statistic 1.34 (1.09 to 1.59) 2.68 (2.55 to 2.82)
ROC statistic 0.688 (0.684 to 0.692) 0.856 (0.851 to0.860)
ROC=receiver operating characteristics.
*Higher values indicate better discrimination.
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population.Giventhat FRAXwasdevelopedin multi-
pleselectedcohortsfromacrosstheworld,themargin-
ally poorer performance is not unexpected.
Our new algorithm does not require any laboratory
testingorclinicalmeasurements.Allthevariablesused
within our algorithm will either be known to an indivi-
dual patient or are collected as part of routine clinical
practice and recorded within an individual patient’s
primary healthcare record. It can be implemented
within clinical computer systems used in primary
care and used to stratify the practice population by
risk on a continuing basis without the need for manual
dataentry.TheQFractureScorescouldthereforeactas
a basis for a systematic population based programme
toidentifyhighriskpatientsforfurtherassessmentand
supporttheimplementationofevolvingclinicalguide-
lines in the UK.
These algorithms, like those that predict cardio-
vascular disease,
1036 rely on routinely collected data
and have the advantage that they are well calibrated
to the setting in which they can be used and have
good levels of discrimination. Assuming the effective-
ness and cost effectiveness of suitable interventions
found in randomised controlled trials
3940 extend to
unselected high risk patients from primary care, the
QFractureScores could be used at a population level
to identify patients at high risk of fracture who might
benefit from more detailed assessment regarding
potential interventions to reduce their risk. At the
level of the individual patient, the algorithm can be
used for self assessment in a web based calculator
(www.qfracture.org), which is similar to the website
for self assessment of cardiovascular disease derived
from the same database (www.qrisk.org). It can help
inform patients regarding their absolute individual
risk so that they can have better information on
whichto basetreatmentdecisions.Someinterventions
can prevent osteoporotic fracture in high risk patients.
Daily supplementation with vitamin D3 and calcium
reduces rates of hip fracture among high risk older
patientsininstitutionalcare.
41Bisphosphonatesreduce
hip and other fracture rates in community dwelling
older women aged under 80.
42 Hip protectors seem
to reduce the incidence of hip fractures in institutional
care, provided that compliance and adherence are
achieved.
43
Hormone replacement therapy and fracture risk
Our study also provides some information on risks
associated with different types and doses of HRT. We
have shown an overall protective effect of HRT with a
decreasedriskwithunopposedoestrogen.Theeffectis
more marked for vertebral, distal radial, and hip frac-
turescombinedratherthanhipfracturealone,whichis
probably because of lower numbers of patients with
hip fracture by individual type of HRT. Our findings
are consistent with those from the Women’s Health
Table 9 |Predicted and observed risk for osteoporotic fracture and hip fracture at 10 years by 10th of predicted risk using QFractureScores in patients aged
30-85
Osteoporotic fracture Hip fracture
Decile
cut-offs*
Incident cases
(column %)
Mean
predicted
risk (%)
Observed
risk (%)
Ratio
predicted/
observed
Decile cut-
offs*
Incident cases
(column %)
Mean
predicted
risk (%)
Observed
risk (%)
Ratio
predicted/
observed
Women
1 — 176 (1.26) 0.41 0.42 0.96 5 (0.09) 0.02 0.01 1.86
2 0.47 223 (1.6) 0.52 0.57 0.92 0.02 11 (0.2) 0.03 0.03 0.94
3 0.57 246 (1.76) 0.63 0.58 1.09 0.03 9 (0.17) 0.04 0.02 2.02
4 0.70 355 (2.54) 0.81 0.81 1.00 0.05 22 (0.41) 0.06 0.04 1.56
5 0.93 500 (3.58) 1.11 1.06 1.05 0.08 55 (1.01) 0.11 0.12 0.88
6 1.32 822 (5.89) 1.59 1.64 0.97 0.14 100 (1.84) 0.19 0.18 1.04
7 1.91 1292 (9.26) 2.39 2.43 0.98 0.25 236 (4.35) 0.38 0.36 1.06
8 2.98 2143 (15.36) 3.88 3.85 1.01 0.56 634 (11.69) 0.94 0.99 0.95
9 5.00 3490 (25.01) 6.69 6.54 1.02 1.50 1494 (27.54) 2.64 2.60 1.02
10 8.75 4705 (33.72) 12.85 12.96 0.99 4.24 2858 (52.69) 8.39 8.04 1.04
Men
1 — 196 (4.34) 0.40 0.42 0.95 7 (0.4) 0.02 0.01 2.32
2 0.43 200 (4.43) 0.45 0.46 0.98 0.03 18 (1.04) 0.03 0.04 0.83
3 0.47 239 (5.29) 0.49 0.49 1.00 0.04 21 (1.21) 0.04 0.04 1.07
4 0.51 221 (4.89) 0.53 0.48 1.11 0.05 22 (1.27) 0.06 0.05 1.10
5 0.56 254 (5.62) 0.58 0.54 1.08 0.06 36 (2.07) 0.07 0.07 1.04
6 0.61 339 (7.5) 0.65 0.71 0.92 0.08 51 (2.93) 0.10 0.08 1.28
7 0.69 345 (7.63) 0.76 0.70 1.08 0.12 83 (4.78) 0.16 0.15 1.06
8 0.84 488 (10.8) 0.97 0.92 1.06 0.20 180 (10.36) 0.29 0.30 0.96
9 1.16 796 (17.61) 1.54 1.47 1.05 0.40 378 (21.75) 0.67 0.66 1.02
10 2.11 1441 (31.89) 4.19 4.20 1.00 1.10 942 (54.2) 3.20 2.68 1.19
*10 year predicted risk %.
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44-46 The loss of the
protective effect of HRT on risk of fracture after stop-
pingtreatmentisconsistentwithsome
4647butnotother
studies.
48 Our study is larger than previous studies
4449
and has a longer follow-up.
44 It also includes a wider
age rangethan in other studies,in which the analysis is
restricted to women 10 years beyond the usual age for
the menopause and those who have more risk factors
andfewermenopausalsymptoms.
44Ourstudypopula-
tionislesslikelytobebiasedthanaclinicaltrialandso
the results should generalise well to the general popu-
lation of women in the UK deciding whether or not to
start or continue HRT.
Validation
We validated the QFractureScore in an independent
sample of general practices from which data had not
been used to develop the algorithm. The QFracture-
Score has good discrimination (that is, ability to sepa-
rate out those who did and did not subsequently
developafracture)andexplainsover60%ofthevaria-
tionforhipfracture.TheDstatistic,whichisameasure
of discrimination appropriate for survival type data,
wassubstantiallyhigherthaninourcardiovasculardis-
ease algorithm
50 and than that reported in some other
studies using the D statistic.
37 This increases the like-
lihoodthatthealgorithmwillaccuratelypredictriskfor
an individual patient. This improved performance of
the hip fracture algorithm compared with overall frac-
ture and other outcomes is probably because of the
strong association between risk of hip fracture and
age and might also reflect some stronger associations
with other risk factors and a more accurate diagnosis,
thus reducing misclassification and potential underes-
timation of associations.
A potential limitation of our validation might be a
degree of overoptimism because, although we used a
completely physically discrete set of general practices
for the validation, these practices use the same clinical
computer system (EMIS) as those used to derive the
algorithm. The EMIS system, however, is currently
inusein60%ofUKgeneralpracticesandsotheQFrac-
tureScore is at least likely to perform well for over half
of the UK’s population. A more stringent test of per-
formance would involve practices using a different
clinical computer system and such a study using the
THIN database is currently under way. Validation of
other disease algorithms in the THIN database have
shown similar levels of performance to the validation
undertaken in a one third sample of the QResearch
database.
1636
Comparison with other risk prediction algorithms
While there is consensus on the need to develop more
accurateestimatesbasedonabsoluteaswellasrelative
risk,thereisnowidelyusedstandardmethodforasses-
sing risk of hip fracture among primary care popula-
tions in the UK.
51 Unlike FRAX, the QFractureScore
can also be used in younger patients (including those
aged 30-39) and can be used to estimate risk at one,
Table 10 |Predicted and observed risks for hip fracture at 10 years in patients aged 40-85 by 10th of predicted risk using
QFractureScore and FRAX scores
QFractureScore FRAX
Mean predicted
risk (%)
Observed risk
(%)
Ratio predicted/
observed
Mean predicted
risk (%)
Observed risk
(%)
Ratio predicted/
observed
Women
1 0.05 0.02 2.47 0.16 0.08 2.03
2 0.08 0.10 0.81 0.16 0.08 2.03
3 0.12 0.14 0.86 0.30 0.17 1.76
4 0.18 0.14 1.30 0.40 0.25 1.60
5 0.29 0.32 0.90 0.54 0.33 1.65
6 0.51 0.47 1.08 0.83 0.61 1.36
7 0.97 1.03 0.95 1.37 1.06 1.29
8 2.01 1.98 1.01 2.46 1.99 1.24
9 4.14 4.30 0.96 4.74 4.34 1.09
10 9.87 9.40 1.05 10.07 9.33 1.08
Men
1 0.04 0.04 1.04 0.10 0.06 1.66
2 0.06 0.06 1.02 0.10 0.06 1.66
3 0.08 0.08 1.01 0.20 0.11 1.82
4 0.11 0.07 1.53 0.20 0.11 1.82
5 0.14 0.15 0.96 0.30 0.17 1.76
6 0.21 0.19 1.09 0.40 0.24 1.67
7 0.32 0.34 0.94 0.59 0.34 1.72
8 0.56 0.46 1.21 0.98 0.52 1.88
9 1.16 1.38 0.84 1.76 1.36 1.30
10 4.12 3.39 1.21 3.87 3.31 1.17
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FRAX. Our new algorithm includes traditional vari-
ables included in the FRAX algorithm, such as age,
smoking, alcohol, rheumatoid arthritis, parental his-
tory of hip fracture, and some secondary causes of
osteoporosis. In addition, our algorithms include
other risk factors as separate variables including type
2diabetes,recordedhistoryoffalls,cardiovasculardis-
ease,liverdisease,malabsorption,otherendocrinedis-
orders, use of tricyclic antidepressants, and type of
HRT and menopausal symptoms in women. By
including more detailed variables we hypothesise that
theQFractureScoreswillbebetteratestimatingriskfor
the individual patient by taking account of more infor-
mation regarding the patient’s history. Our algorithm
differs from FRAX because the QFractureScores pre-
dict risk among patients without a recorded history of
previous fracture, whereas FRAX can be used to pre-
dict future risk of fracture in those already known to
have a previous fracture.
Our analysis shows some improved discrimination
oftheQFractureScorecomparedwiththeFRAXalgo-
rithm for hip fracture, based on the D statistic, which
had values that were 0.11 higher in women and 0.17
higherinmen.AdifferenceinDstatisticof0.1ormore
can indicate an important difference in prognostic
separation of survival curves between two risk
algorithms.
37 It is important to note, however, that the
QFractureScore was developed in a primary care
populationandsowouldbeexpectedtoperformbetter
in this setting.
OnepotentiallimitationoftheQFractureScorescom-
pared with FRAX is that they don’t include measure-
ment of bone mineral density, whereas FRAX has two
versions, one with and one without this measurement.
ThispotentiallylimitsthevalueoftheQFractureScores
whenbonemineraldensityisknownbutdoesmeanthat
thescorecanbeappliedwithouttheneedforexpensive
andinconvenientteststoidentifyhighriskpatientswho
might then benefit from further investigation. Another
potential limitation of the QFractureScores is that they
aremorecomplexthanFRAXandmightbemorediffi-
cult to implement. The main use of the QFracture-
Scores, however, is likely to be integrated into general
practice clinical computer systems, as well as a web
based calculator, where software can automatically
extract the necessary variables, perform the calcula-
tions, and present the results to the clinician and indivi-
duals as appropriate. Also, a score that includes more
variables islikely tobetterpredictrisk for anindividual
especially if that person has complex comorbidities.
Future research should address whether a targeted
approachtocasefindingbasedonthe QFractureScores
results in measurable clinical benefit.
Ouralgorithmalsoimprovesontherecentalgorithm
basedonthe Women’sHealthInitiativecohort
25asitis
estimated over a longer period than five years and
includes additional variables, such as HRT, that are
known to affect risk of fracture. It also has improved
validation statistics; our ROC value for hip fracture in
women was 0.890 (0.889 to 0.892), which is substan-
tially higher than the value of 0.80 (0.77 to 0.82)
reported in the Women’s Health Initiative.
25
Methodological considerations
Generalisability and measurement of outcomes
A particular strength of our study is its prospective
cohort design based on the analysis of a large
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Fig 2 | Predicted and observed risk of hip fracture with QFractureScore and FRAX
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Our main outcome was hip, vertebral, or distal radial
fracture recorded by a clinician on the clinical compu-
tersystem.Similarstudiesusingsimilardatabaseshave
confirmed the diagnosis of hip fracture on compu-
terised general practice records in over 90% of
cases.
26 Our rates of hip fracture were similar to those
obtained in other similar general practice databases
such as GPRD.
52-54 Our rates tend to be higher than
some population based cohorts,
2546 which might be
because of some under-ascertainment due to self
reported events reported by questionnaire rather than
by analysis of data prospectively recorded on the
patients’ medical records, as in our study.
In our study, 38% of osteoporotic fractures were hip
fractures, which is similar to the figure reported
elsewhere.
54 There might be under-ascertainment or
under-recordingofvertebralfractureasitisnotalways
associated with pain and loss of function so the patient
mightnotpresenttothegeneralpractitioner.Failureto
identify and record a diagnosis on the computer when
a patient is identified is possible and is part of the justi-
fication for having a targeted approach.
55
Predictor variables
Ourstudyhasgoodvalidityasourhazardratiosforrisk
of hip fracture with use of corticosteroids, alcohol,
smoking, diabetes, and presence of a parental history
of osteoporosis were similar to those found in other
studies.
20222325455657 In particular, our analysis sup-
ports a dose-response relation for current smokers
with lower risks among former smokers.
19-21 We also
foundnoassociationbetweenhipfractureanddepriva-
tion, which confirmed findings reported elsewhere.
58
We have not included bone mineral density as the
score is seldomrecordedin general practicerecords, it
is likely to be measured in only a selected high risk
population, and it is costly to measure. The score
could, however, be used to select high risk patients
for measurement of bone mineral density as part of
their assessment after identification of their high risk
status for fracture. Previous fracture was not included
asthesepeoplehavealreadyexperiencedtheoutcome
of interest, and it could be argued that they are auto-
matically at high risk and all such patients should be
managed as high risk patients in a secondary preven-
tion context.
Sources of bias and unmeasured confounding
As with all epidemiological studies, we need to con-
sider potential sources of bias and confounding. Our
predictor variables were recorded by clinicians on the
clinical computer system before the diagnosis of frac-
ture and so will not have been subject to recall bias.
Some of our predictor variables are objective clinical
diagnoses (such as type 2 diabetes, cardiovascular dis-
ease, or rheumatoid arthritis), others are directly mea-
sured values (such as BMI). Several variables,
however, are those reported by patients, such as alco-
hol, smoking, and parental history of hip fracture. As
suchthesevariablesmightbesubjecttoinformationor
reporting bias (patients, for example, might not accu-
rately report their alcohol intake or use of cigarettes or
might not be asked about or be aware of a relevant
family history). As the QFractureScores are intended
for use within general practice clinical computer sys-
tems,however,similarconditionswillapplyandsothe
variables incorporated in the algorithm have intrinsic
face validity. We used the entire eligible population
registeredwitharandomtwothirdssampleofpractices
contributing to the QResearchdatabase from England
andWales.Consequently,thepopulationisunlikelyto
be affected by selection bias, in contrast with purpose
designed clinical cohorts or clinical trials.
4659
We did not have objective measurements of some
otherfactorsthatmightaffectfracturerisk,suchasphy-
sical activity and ethnicity. The former is not reliably
recordedonclinicalcomputersystems,andanalysisof
the latterwaslimitedin thisstudybecauseof lownum-
bers of elderly patients with fractures from different
ethnic groups.
Missing data
Another potential limitation of our study is that some
patients had missing values for alcohol use, BMI, or
smoking status. We therefore used the technique of
multipleimputationtosubstitutemissingvaluesrather
than exclude these patients as this is a less biased
approachthatmakesthe mostefficientuseofavailable
data.
3234 For other variables in the algorithm we
assumed that if there was no recorded value of a diag-
nosis, prescription, or family history then the patient
did not have that exposure, which might have led to
some misclassification.
Conclusions
Our new risk prediction algorithms for osteoporotic
fractureandhipfracturedonotrequirelaboratorymea-
surementandcanbereadilyusedinprimarycareorfor
individual self assessment (www.qfracture.org). The
algorithms potentially improve on other algorithms by
WHAT IS ALREADY KNOWN ON THIS TOPIC
Osteoporotic fracture is a major cause of morbidity, and interventions exist that can help
reduce risk of fracture
Severalinternationalguidelinessuggestatargetedapproachforidentifyinghighriskpatients
likely to benefit from interventions based on a 10 year absolute fracture risk
Risk prediction algorithms tend to perform best when they are developed in the clinical
setting in which they will be applied
WHAT THIS STUDY ADDS
These new risk prediction algorithms (QFractureScores) for osteoporotic fracture and hip
fracture do not require laboratory measurement and so can be used in primary care or for
individual self assessment (www.qfracture.org)
Thenew algorithmsinclude additionalvariables andwere developedinandcould beusedin
large representative primary care populations
The validation statistics, especially for the hip fracture algorithm, suggest that the
QFractureScores are likely to be effective at identifying patients at high risk of fracture within
primary care in the UK and showed improved performance compared with FRAX
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tionalscores.Thevalidationstatisticsforthehipfracture
algorithmsuggestthatthemodelsarelikelytobeatleast
aseffectiveatidentifyingpatientsathighriskofhipfrac-
ture within primary care as the FRAX algorithm.
Further validation studies are needed to test the perfor-
mance of these algorithms in independent populations
that are representative of the setting where the algo-
rithms are likely to be used.
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